Scinai Immunotherapeutics Ltd. (FRA:2F5)

Scinai Immunotherapeutics Statistics

Total Valuation

FRA:2F5 has a market cap or net worth of EUR 2.74 million. The enterprise value is 8.76 million.

Market Cap	2.74M
Enterprise Value	8.76M

Important Dates

The last earnings date was Monday, November 24, 2025.

Earnings Date	Nov 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+157.30%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.78M

Valuation Ratios

The trailing PE ratio is 9.28.

PE Ratio	9.28
Forward PE	n/a
PS Ratio	2.81
PB Ratio	0.41
P/TBV Ratio	1.44
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	29.64
EV / Sales	8.88
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.80

Financial Position

The company has a current ratio of 0.71, with a Debt / Equity ratio of 0.30.

Current Ratio	0.71
Quick Ratio	0.53
Debt / Equity	0.30
Debt / EBITDA	n/a
Debt / FCF	-0.41
Interest Coverage	-6.67

Financial Efficiency

Return on equity (ROE) is 1,791.99% and return on invested capital (ROIC) is -44.45%.

Return on Equity (ROE)	1,791.99%
Return on Assets (ROA)	-39.55%
Return on Invested Capital (ROIC)	-44.45%
Return on Capital Employed (ROCE)	-86.89%
Revenue Per Employee	31,506
Profits Per Employee	9,531
Employee Count	31
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -74.22% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-74.22%
50-Day Moving Average	1.19
200-Day Moving Average	2.39
Relative Strength Index (RSI)	39.40
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.18

Income Statement

In the last 12 months, FRA:2F5 had revenue of EUR 976,671 and earned 295,471 in profits. Earnings per share was 0.22.

Revenue	976,671
Gross Profit	-1.44M
Operating Income	-7.19M
Pretax Income	4.38M
Net Income	295,471
EBITDA	-5.74M
EBIT	-7.19M
Earnings Per Share (EPS)	0.22

Balance Sheet

The company has 842,134 in cash and 2.01 million in debt, giving a net cash position of -1.16 million.

Cash & Cash Equivalents	842,134
Total Debt	2.01M
Net Cash	-1.16M
Net Cash Per Share	n/a
Equity (Book Value)	6.69M
Book Value Per Share	1.25
Working Capital	-522,821

Cash Flow

In the last 12 months, operating cash flow was -4.84 million and capital expenditures -13,624, giving a free cash flow of -4.86 million.

Operating Cash Flow	-4.84M
Capital Expenditures	-13,624
Free Cash Flow	-4.86M
FCF Per Share	n/a

Margins

Gross margin is -146.99%, with operating and profit margins of -736.36% and 448.39%.

Gross Margin	-146.99%
Operating Margin	-736.36%
Pretax Margin	448.39%
Profit Margin	448.39%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:2F5 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-157.30%
Shareholder Yield	-157.30%
Earnings Yield	10.78%
FCF Yield	-177.16%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on May 21, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date	May 21, 2024
Split Type	Reverse
Split Ratio	0.1

Scores

FRA:2F5 has an Altman Z-Score of -16.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-16.28
Piotroski F-Score	3